Australia Ophthalmic Devices Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The Australian ophthalmic devices market encompasses a broad range of products including intraocular lenses, surgical equipment, diagnostic devices, and vision correction products used across public and private healthcare settings. The market reflects a mature healthcare system with widespread access to advanced eye care services and strong adoption of innovative technologies. Government-supported public health infrastructure through Medicare complements a robust private sector, creating sustained demand across all device categories.

• •Market valued at approximately $1.98 billion in 2025 with steady expansion forecast through 2030
• •Australia maintains one of the highest per-capita healthcare spending levels in the Asia Pacific region
• •Strong public-private healthcare ecosystem supports consistent device procurement across the care continuum

An aging demographic profile is the primary market catalyst, with increasing incidence of age-related eye conditions such as cataracts, age-related macular degeneration, and glaucoma driving surgical device demand. Rising prevalence of myopia and other refractive errors among younger populations is expanding the vision correction segment, including contact lenses and refractive surgery equipment. Favorable Medicare reimbursement schemes and growing overall healthcare expenditure provide the financial framework supporting market expansion.

• •Australia's population aged 65 and over is projected to reach approximately 20% by 2030, increasing demand for cataract and glaucoma interventions
• •Rising myopia rates, particularly among young Australians, drive growth in diagnostic equipment and vision correction devices
• •Medicare Benefits Schedule coverage for ophthalmology procedures ensures broad patient access and consistent demand

The market is segmented by product type, with intraocular lenses representing the largest category, followed by glaucoma devices, corneal implants, and diagnostic and surgical equipment. New South Wales and Victoria account for the majority of market activity due to higher population density and concentrated specialist services, though Western Australia and Queensland are experiencing above-average growth. The segment breakdown reflects Australia's high surgical volume for cataract procedures, among the highest per capita globally, and growing adoption of minimally invasive glaucoma treatments.

• •Intraocular lenses constitute the largest segment, driven by Australia's high cataract surgery rates of approximately 10,000 procedures per million population annually
• •New South Wales and Victoria together represent roughly 60% of national ophthalmic device consumption
• •Glaucoma surgery devices and corneal implants are the fastest-growing product categories due to aging-related disease prevalence

What are the recent trends and outlook?

Technological advancement in premium intraocular lenses, including multifocal and extended depth-of-focus designs, continues to drive premiumization of the cataract surgery market and expand addressable patient populations. Increasing shift toward outpatient day-surgery models and minimally invasive procedures supports sustained market growth by reducing procedural costs and increasing procedural volumes. The market is expected to maintain its 5.5% CAGR trajectory through 2030, with emerging innovations in sustained-release drug delivery devices and gene therapy treatments presenting longer-term growth opportunities.

• •Adoption of femtosecond laser-assisted cataract surgery and premium IOL technologies is expanding the high-value segment of the market
• •Tele-ophthalmology and AI-assisted diagnostic screening tools are gaining adoption in regional and remote area healthcare delivery
• •Pipeline innovations in sustained-release glaucoma treatments and corneal inlays are positioned to drive the next wave of market growth through 2032